Evommune presents Phase 2a EVO301 data
Evommune said it presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the European Academy of Dermatology and Venereology Congress.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Evommune Presents Phase 2a Data for EVO301 in Atopic Dermatitis
Evommune, Inc. shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis at the European Academy of Dermatology and Venereology Congress.